Published in Ann Oncol on January 19, 2009
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer (2011) 1.45
Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) (2013) 1.42
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer (2014) 1.41
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver (2013) 1.28
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol (2011) 1.20
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer (2014) 1.12
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer (2014) 1.10
MET amplification as a potential therapeutic target in gastric cancer. Oncotarget (2013) 1.09
Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer (2013) 1.08
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer (2015) 1.07
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer (2014) 1.05
Strategies for treating liver metastasis from gastric cancer. Surg Today (2010) 1.02
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer (2011) 1.00
Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer (2011) 1.00
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs (2010) 0.99
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs (2009) 0.99
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs (2011) 0.98
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep (2016) 0.97
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer (2012) 0.96
Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer (2012) 0.94
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs (2010) 0.93
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer (2011) 0.92
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci (2014) 0.92
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer (2016) 0.92
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer (2011) 0.91
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer. Gastric Cancer (2013) 0.90
Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther (2015) 0.89
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial. Medicine (Baltimore) (2015) 0.89
FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med (2014) 0.89
Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer (2011) 0.89
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. Chin J Cancer Res (2011) 0.88
Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol (2016) 0.88
Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol (2011) 0.87
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol (2012) 0.87
Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res (2011) 0.87
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer (2010) 0.86
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget (2015) 0.86
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer (2013) 0.86
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol (2011) 0.86
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer (2012) 0.85
5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci (2015) 0.85
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes (2014) 0.85
VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World J Surg (2011) 0.85
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. Gastric Cancer (2014) 0.85
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. Gastric Cancer (2014) 0.84
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol (2011) 0.84
Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol (2013) 0.84
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol (2009) 0.84
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs (2011) 0.83
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Invest New Drugs (2013) 0.83
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol (2012) 0.83
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis. PLoS One (2014) 0.83
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer (2011) 0.82
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol (2010) 0.82
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther (2011) 0.82
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer (2013) 0.82
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer (2013) 0.81
Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol (2016) 0.81
Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer (2012) 0.81
Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res (2009) 0.81
Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience. World J Gastroenterol (2013) 0.81
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol (2014) 0.80
Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer. Mol Clin Oncol (2014) 0.79
Global chemotherapy development for gastric cancer. Gastric Cancer (2016) 0.79
Clinical utility of ramucirumab in advanced gastric cancer. Biologics (2015) 0.79
Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells. Oncol Lett (2014) 0.79
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs (2012) 0.79
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget (2016) 0.79
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol (2014) 0.79
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Invest New Drugs (2012) 0.79
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer (2016) 0.79
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis. World J Gastroenterol (2015) 0.79
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol (2016) 0.78
Gastric cancer: past progress and present challenges. Gastric Cancer (2014) 0.78
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One (2014) 0.78
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer (2012) 0.78
Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials. Gastrointest Cancer Res (2009) 0.78
Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol (2010) 0.78
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors. J Cancer Res Clin Oncol (2014) 0.78
Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis. Curr Oncol (2011) 0.78
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer (2011) 0.78
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy. Surg Today (2016) 0.77
Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. Gastric Cancer (2011) 0.77
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol (2014) 0.77
Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. J Cancer Res Clin Oncol (2012) 0.77
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics (2003) 32.92
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A (1990) 16.34
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA (1998) 11.90
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
MCML--Monte Carlo modeling of light transport in multi-layered tissues. Comput Methods Programs Biomed (1995) 11.10
Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med (2001) 10.36
Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature (2005) 10.04
Highly pathogenic H5N1 influenza virus infection in migratory birds. Science (2005) 9.64
Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A (2006) 9.26
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 8.80
An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature (1994) 8.60
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet (1998) 7.89
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
TRAF6 is a signal transducer for interleukin-1. Nature (1996) 7.38
Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem (2001) 7.35
Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature (1995) 7.05
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 6.91
Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell (2000) 6.70
Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (2001) 6.47
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A (1980) 6.31
A global profile of germline gene expression in C. elegans. Mol Cell (2000) 5.97
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 5.92
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell (1997) 5.92
The transcription factor associated Ccr4 and Caf1 proteins are components of the major cytoplasmic mRNA deadenylase in Saccharomyces cerevisiae. Cell (2001) 5.86
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 5.74
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature (2013) 5.44
Genetic diversity and disease control in rice. Nature (2000) 5.34
An essential role for Rac in Ras transformation. Nature (1995) 5.34
Structure of the replicating complex of a pol alpha family DNA polymerase. Cell (2001) 5.26
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19
Indium phosphide nanowires as building blocks for nanoscale electronic and optoelectronic devices. Nature (2001) 5.09
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell (1998) 4.78
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell (1999) 4.76
Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med (2000) 4.54
Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A (2006) 4.49
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res (2001) 4.38
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature (1999) 4.29
Demethylation-induced developmental pleiotropy in Arabidopsis. Science (1996) 4.25
Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS (2000) 4.24
Improved stability of Drosophila larval neuromuscular preparations in haemolymph-like physiological solutions. J Comp Physiol A (1994) 4.24
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys (1992) 4.12
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler (1994) 4.09
A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A (2000) 4.06
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med (2011) 4.04
Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97
Anthropogenic warming of Earth's climate system. Science (2001) 3.94
Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol (2001) 3.92
Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (1995) 3.92
B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med (2000) 3.89
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J (2005) 3.84
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell (1999) 3.83
Two regulatory genes of the maize anthocyanin pathway are homologous: isolation of B utilizing R genomic sequences. Plant Cell (1989) 3.83
Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol (1992) 3.82
Quantum annealing with manufactured spins. Nature (2011) 3.81
SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet (1998) 3.79
Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 3.76
Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy (2007) 3.75
Pooled exposure-response analyses and risk assessment for lung cancer in 10 cohorts of silica-exposed workers: an IARC multicentre study. Cancer Causes Control (2001) 3.74
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science (2000) 3.72
Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science (1999) 3.71
Health literacy and health-related knowledge among persons living with HIV/AIDS. Am J Prev Med (2000) 3.70
Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell (1995) 3.70
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
A role for Rho in Ras transformation. Proc Natl Acad Sci U S A (1995) 3.59
TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell (1995) 3.56
Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature (1999) 3.51
Multiferroic BaTiO3-CoFe2O4 Nanostructures. Science (2004) 3.49
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Highly conserved core domain and unique N terminus with presumptive regulatory motifs in a human TATA factor (TFIID). Nature (1990) 3.42
Enrichment of gene-coding sequences in maize by genome filtration. Science (2003) 3.41
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (1995) 3.39